News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
267,681 Results
Type
Article (13890)
Company Profile (102)
Press Release (253689)
Multimedia
Podcasts (49)
Webinars (11)
Section
Business (88100)
Career Advice (465)
Deals (15355)
Drug Delivery (67)
Drug Development (36625)
Employer Resources (49)
FDA (6309)
Job Trends (6209)
News (150331)
Policy (14062)
Tag
Academia (441)
Accelerated approval (3)
Adcomms (6)
Allergies (41)
Alliances (23294)
ALS (39)
Alzheimer's disease (402)
Antibody-drug conjugate (ADC) (54)
Approvals (6357)
Artificial intelligence (130)
Autoimmune disease (9)
Automation (5)
Bankruptcy (150)
Best Places to Work (4370)
BIOSECURE Act (9)
Biosimilars (59)
Biotechnology (40)
Bladder cancer (23)
Brain cancer (18)
Breast cancer (104)
Cancer (781)
Cardiovascular disease (81)
Career advice (409)
Career pathing (12)
CAR-T (27)
CDC (3)
Cell therapy (97)
Cervical cancer (5)
Clinical research (31146)
Collaboration (409)
Compensation (186)
Complete response letters (17)
COVID-19 (765)
CRISPR (27)
C-suite (159)
Cystic fibrosis (42)
Data (859)
Denatured (15)
Depression (13)
Diabetes (89)
Diagnostics (1333)
Digital health (1)
Diversity (2)
Diversity, equity & inclusion (14)
Drug discovery (66)
Drug pricing (77)
Drug shortages (12)
Duchenne muscular dystrophy (47)
Earnings (32506)
Editorial (14)
Employer branding (4)
Employer resources (44)
Events (37941)
Executive appointments (456)
FDA (6862)
Friedreich's ataxia (2)
Frontotemporal dementia (1)
Funding (263)
Gene editing (45)
Generative AI (9)
Gene therapy (112)
GLP-1 (368)
Government (1320)
Grass and pollen (3)
Guidances (77)
Healthcare (3570)
Huntington's disease (5)
IgA nephropathy (16)
Immunology and inflammation (39)
Immuno-oncology (2)
Indications (18)
Infectious disease (800)
Inflammatory bowel disease (59)
Inflation Reduction Act (6)
Influenza (14)
Intellectual property (59)
Interviews (59)
IPO (5901)
IRA (30)
Job creations (2054)
Job search strategy (373)
Kidney cancer (7)
Labor market (17)
Layoffs (188)
Leadership (4)
Legal (3441)
Liver cancer (19)
Lung cancer (108)
Lymphoma (67)
Machine learning (4)
Management (16)
Manufacturing (194)
MASH (39)
Medical device (1284)
Medtech (1286)
Mergers & acquisitions (9703)
Metabolic disorders (294)
Multiple sclerosis (25)
NASH (14)
Neurodegenerative disease (30)
Neuropsychiatric disorders (10)
Neuroscience (620)
NextGen: Class of 2025 (1588)
Non-profit (597)
Now hiring (11)
Obesity (167)
Opinion (127)
Ovarian cancer (25)
Pain (65)
Pancreatic cancer (25)
Parkinson's disease (51)
Partnered (7)
Patents (143)
Patient recruitment (36)
Peanut (12)
People (29135)
Pharmaceutical (64)
Pharmacy benefit managers (13)
Phase I (8108)
Phase II (13175)
Phase III (11828)
Pipeline (622)
Policy (89)
Postmarket research (1401)
Preclinical (3257)
Press Release (25)
Prostate cancer (58)
Psychedelics (8)
Radiopharmaceuticals (123)
Rare diseases (190)
Real estate (2639)
Recruiting (17)
Regulatory (10231)
Reports (14)
Research institute (568)
Resumes & cover letters (55)
Rett syndrome (1)
RNA editing (4)
RSV (8)
Schizophrenia (43)
Series A (48)
Series B (16)
Service/supplier (3)
Sickle cell disease (33)
Special edition (6)
Spinal muscular atrophy (77)
Sponsored (7)
Startups (1633)
State (2)
Stomach cancer (3)
Supply chain (34)
Tariffs (42)
The Weekly (32)
Vaccines (171)
Venture capital (16)
Weight loss (101)
Women's health (8)
Worklife (4)
Date
Today (36)
Last 7 days (196)
Last 30 days (916)
Last 365 days (11280)
2025 (5540)
2024 (12501)
2023 (14247)
2022 (19556)
2021 (20068)
2020 (19032)
2019 (14885)
2018 (11713)
2017 (13888)
2016 (13129)
2015 (15472)
2014 (12419)
2013 (10592)
2012 (11395)
2011 (11922)
2010 (10888)
Location
Africa (314)
Alabama (15)
Alaska (1)
Arizona (60)
Arkansas (3)
Asia (20306)
Australia (2629)
California (2083)
Canada (1038)
China (314)
Colorado (81)
Connecticut (83)
Delaware (75)
Europe (39800)
Florida (407)
Georgia (45)
Idaho (9)
Illinois (232)
India (16)
Indiana (155)
Iowa (1)
Japan (125)
Kansas (62)
Kentucky (15)
Louisiana (2)
Maine (2)
Maryland (304)
Massachusetts (1784)
Michigan (34)
Minnesota (108)
Mississippi (1)
Missouri (23)
Montana (8)
Nebraska (6)
Nevada (12)
New Hampshire (6)
New Jersey (908)
New Mexico (7)
New York (621)
North Carolina (439)
North Dakota (2)
Northern California (870)
Ohio (54)
Oklahoma (4)
Oregon (16)
Pennsylvania (508)
Puerto Rico (9)
Rhode Island (10)
South America (503)
South Carolina (5)
Southern California (873)
Tennessee (39)
Texas (277)
United States (8584)
Utah (42)
Virginia (96)
Washington D.C. (38)
Washington State (137)
West Virginia (1)
Wisconsin (21)
267,681 Results for "scilex pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Scilex Holding Company Announces Publication on GLOPERBA® Dosing Adjustments in Peer-Review Journal
June 6, 2025
·
7 min read
Press Releases
Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex’s Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from January 28, 2025 to April 11, 2025
March 10, 2025
·
7 min read
Press Releases
Scilex Holding Company Announces FDA Has Approved Our Request for the Orphan Drug Designation for Colchicine for the Treatment of Pericarditis
April 16, 2025
·
8 min read
Biotech Bay
Scilex Holding Company Provides Information to Scilex Stockholders Regarding Manipulative and Naked Short Selling of Scilex Common Stock
Scilex Holding Company, an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, provides information to its stockholders regarding short selling of Scilex common stocks traded on the Nasdaq Capital Market.
May 13, 2024
·
12 min read
Press Releases
Scilex Holding Company Announces Approval of a New Drug Submission (NDS) from the Health Canada’s Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for ELYXYB®’s Acute Treatment of Migraine With or Without Aura in Canada
April 16, 2025
·
8 min read
Policy
Virpax Pharmaceuticals Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc.
Virpax ® Pharmaceuticals, Inc. today announced that it has entered into a term sheet to settle the litigation with the Company and Sorrento Therapeutics, Inc. (Sorrento) and Scilex Pharmaceuticals, Inc. (Scilex and Sorento, collectively, the “Plaintiffs”).
February 27, 2024
·
5 min read
Press Releases
Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex’s Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from November 7, 2024 to January 28, 2025
December 30, 2024
·
7 min read
Press Releases
Scilex Holding Company Announces Extension of the Maturity Date of its Secured Promissory Note Issued to Oramed Pharmaceuticals Inc. to December 31, 2025
January 21, 2025
·
6 min read
Press Releases
Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Dividend Stock Previously Distributed by Sorrento to its Stockholders as a Dividend to April 14, 2025
January 31, 2025
·
7 min read
Press Releases
Scilex Holding Company sets November 7, 2024 as the Record Date for a Dividend of Preferred Stock Exchangeable for up to 10% of Scilex’s Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary
October 28, 2024
·
14 min read
1 of 26,769
Next
